UCB (OTCMKTS:UCBJY) Rating Increased to Moderate Sell at Jefferies Financial Group

Jefferies Financial Group upgraded shares of UCB (OTCMKTS:UCBJY) to a moderate sell rating in a research report released on Sunday morning,Zacks.com reports.

A number of other research firms also recently issued reports on UCBJY. The Goldman Sachs Group raised shares of UCB to a “strong-buy” rating in a research note on Wednesday, July 16th. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a report on Friday, August 29th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, UCB has an average rating of “Strong Buy”.

UCB Stock Performance

Shares of UCB stock opened at $139.90 on Friday. The business has a 50 day moving average of $130.10 and a 200 day moving average of $107.13. UCB has a 52 week low of $71.16 and a 52 week high of $151.76.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.